Ligand Pharmaceuticals (LGND) Free Cash Flow (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Free Cash Flow data on file, last reported at $48.5 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 288.87% year-over-year to $48.5 million; the trailing twelve-month figure through Mar 2026 stood at $123.3 million (up 141.98% YoY), and the FY2025 full-year result was $49.1 million, down 48.39% from the prior year.
• Free Cash Flow rose to $48.5 million in Q1 2026, from $45.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $48.5 million in Q1 2026 to a low of -$25.7 million in Q1 2025.
• A 5-year average of $21.3 million and a median of $18.6 million in 2024 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow soared 617.0% in 2024 and sank 237.75% in 2025, its largest moves.
• Tracing LGND's Free Cash Flow over 5 years: stood at $39.2 million in 2022, then slumped by 71.49% to $11.2 million in 2023, then soared by 148.54% to $27.8 million in 2024, then soared by 64.63% to $45.7 million in 2025, then gained by 6.05% to $48.5 million in 2026.
• Business Quant data shows LGND's Free Cash Flow at $48.5 million in Q1 2026, $45.7 million in Q4 2025, and $13.1 million in Q3 2025.